Tesamorelin has a different profile from most peptides people discuss for body composition: it is an FDA-approved prescription drug. Sold as Egrifta, it was approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its effect on visceral fat has since drawn interest from people focused on physique, metabolic health and healthy aging.
Unlike growth hormone injections, tesamorelin doesn't replace growth hormone. It signals the pituitary gland to release more of the body's own, keeping the normal feedback system in place.
In this guide, we cover:
-
What tesamorelin is and how it works
-
What clinical trials show about its benefits
-
Approved dosing and how it is used off-label
-
What is known about combining it with supplements and other peptides
-
Who it is approved for, and who should avoid it
-
Common beginner mistakes
-
Legal status and drug testing
What Is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), the signal the brain sends to trigger growth hormone release. A trans-3-hexenoyl group added to one end protects it from rapid breakdown, so it lasts longer than natural GHRH.
It was developed by Theratechnologies and first approved by the FDA on November 10, 2010. It is the only FDA-approved drug specifically for reducing visceral fat in HIV-associated lipodystrophy.
Because it acts on the GHRH receptor, it does not have the effects on cortisol and prolactin seen with some ghrelin-mimicking peptides such as GHRP-6.
How Tesamorelin Works
-
Tesamorelin is injected under the skin and binds GHRH receptors on the front of the pituitary gland.
-
The pituitary releases growth hormone in its natural pulsing pattern.
-
Growth hormone signals the liver to make IGF-1, which drives many of growth hormone's effects on tissue.
-
Growth hormone also promotes fat breakdown, with a notable effect on visceral fat.
Because it works upstream, the body's feedback loop stays intact. Rising IGF-1 still tells the system to slow growth hormone release, which helps keep levels within a more natural range than injected growth hormone.
Benefits of Tesamorelin
Reduces Visceral Fat
This is tesamorelin's proven benefit. In Phase 3 trials, 2 mg daily cut visceral fat by about 15% over 26 weeks in adults with HIV and excess abdominal fat. Fat under the skin barely changed. A 2012 analysis by Stanley and colleagues found that people whose visceral fat fell the most also saw the biggest improvements in triglycerides and other metabolic markers.
The fat tends to return after treatment stops.
Reduces Liver Fat
Trials in people with HIV found tesamorelin lowered liver fat. A 2019 Lancet HIV study also found less progression of liver fibrosis over a year.
Cognitive Function
A 2012 study in older adults, with and without mild cognitive impairment, found 20 weeks of tesamorelin improved some measures of executive function compared with placebo.
Muscle and Recovery
Higher growth hormone and IGF-1 support muscle protein synthesis and connective tissue repair in general. Trials of tesamorelin reported small gains in lean mass, but it has not been tested as a muscle-building or injury-recovery treatment.
Healthy Aging
Growth hormone declines with age, which is why tesamorelin draws interest from people focused on longevity. Whether raising growth hormone in healthy older adults improves long-term health is not established, and higher IGF-1 has its own long-term questions.
Combining Tesamorelin With Supplements
No trial has tested tesamorelin with specific supplements. These are commonly discussed because they have their own evidence for the same goals:
-
Protein: adequate intake helps preserve muscle during fat loss.
-
Sleep: most natural growth hormone is released during deep sleep, and poor sleep worsens insulin sensitivity.
-
Resistance training: the best-supported way to build and keep muscle at any age.
People with blood sugar issues should be cautious about adding anything that affects glucose without checking with their doctor.
Combining Tesamorelin With Other Peptides
No clinical trial has tested tesamorelin with any other peptide.
-
Ipamorelin: a ghrelin-receptor agonist often paired with GHRH analogs, since the two act on growth hormone through different receptors.
-
CJC-1295: another GHRH analog. Combining two GHRH analogs targets the same receptor and adds little rationale.
-
BPC-157 and TB-500: discussed for recovery alongside tesamorelin's metabolic effects.
-
GHK-Cu: discussed for skin and hair.
Stacking several compounds that raise growth hormone can push IGF-1 higher than intended and increase effects on blood sugar. Anyone combining them should do so under medical supervision with IGF-1 monitoring.
Who Tesamorelin Is For
Approved Use
Adults with HIV-associated lipodystrophy and excess abdominal fat.
Off-Label Interest
-
People with stubborn visceral fat despite diet and exercise
-
Adults interested in metabolic health and aging
-
Physique athletes, who should note it is banned in tested sport
Off-label use requires a prescription and a physician's oversight.
Who Should Avoid It
-
People with active cancer, since higher growth hormone and IGF-1 could promote tumor growth
-
People whose pituitary system has been disrupted by surgery, radiation or tumors
-
People with known hypersensitivity to tesamorelin
-
People who are pregnant
Common Beginner Mistakes
Expecting Fast Results
The trials ran 26 weeks. Changes in visceral fat build over months, not days.
Treating It as a Weight-Loss Drug
Tesamorelin targets visceral fat. Its effect on overall weight and fat under the skin is small, and the label says it is not for weight loss.
Skipping Bloodwork
IGF-1 and blood glucose should be monitored. Higher IGF-1 is the intended effect, but too high is a risk.
Stacking Multiple Growth Hormone Agents
Layering several growth hormone-raising compounds adds to the risks without any tested benefit.
Ignoring Diet and Training
Tesamorelin was not tested as a replacement for diet and exercise, which drive most body composition change.
Using Unregulated Products
Research-grade tesamorelin isn't the same as the FDA-approved product, and quality can vary.
Side Effects
The most common side effects in trials were:
-
Joint pain
-
Injection-site redness, itching or pain
-
Pain in the arms and legs
-
Swelling in the hands and feet
-
Muscle pain
Other label warnings:
-
Blood sugar: can worsen glucose tolerance. A 2017 trial in people with type 2 diabetes found no meaningful worsening of glucose control over 12 weeks, but monitoring is still advised.
-
Antibodies: some patients develop antibodies to tesamorelin.
-
Long-term cardiovascular safety has not been established.
Legal Status and Drug Testing
-
FDA approved as Egrifta, Egrifta SV and Egrifta WR for excess abdominal fat in adults with HIV-associated lipodystrophy.
-
Prescription only. Use for other purposes is off-label and requires a prescriber.
-
Not a controlled substance. Tesamorelin is not scheduled under the Controlled Substances Act.
-
Anti-doping: GHRH and its analogs, including tesamorelin, are prohibited at all times under the World Anti-Doping Code.
Conclusion: Is Tesamorelin Worth Considering?
Tesamorelin stands out among growth hormone peptides because it has what the others lack: FDA approval, large randomized trials and an official label. Its effect on visceral fat is well documented, along with improvements in liver fat and triglycerides.
It also has clear limits. It isn't a weight-loss drug, results fade after stopping, and its effects in people without HIV-associated lipodystrophy have been studied less. It requires a prescription, monitoring of IGF-1 and blood sugar, and a physician's involvement.
For people with stubborn visceral fat who are already working on diet, training and sleep, it is one of the best-studied options in its class.
Disclaimer
This article is for educational and informational purposes only. Tesamorelin is FDA-approved only for the indication described above. Dosing information reflects the approved label, published trials and protocols reported online, and is not a recommendation for use. Nothing here is medical advice. The Peptide Library is operated in connection with ZenoPeps. Research products are not intended for human consumption.
References
-
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007.
-
Falutz J, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS, 2008.
-
Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 2012.
-
Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV, 2019.
-
Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 2012.
-
Clemmons DR, et al. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes. PLoS One, 2017.
-
Egrifta WR dosage and prescribing information, Drugs.com.